The datasets generated for this study can be found in the GenBank under the accession numbers MN136770--MN136778.

Introduction {#sec001}
============

Microsporidia are fungal obligate intracellular pathogens. Among at least 10 genera including 17 species infecting humans, *Enterocytozoon bieneusi* is the most frequently detected pathogen causing microsporidiosis \[[@pntd.0008293.ref001]\]. Infection by *E*. *bieneusi* may have no symptoms or may cause persistent diarrhea, vomiting and a wasting syndrome, dissemination and presence in other organs, particularly in immunocompromised individuals such as human immunodeficiency virus (HIV)-infected individuals, organ transplant recipients or cancer patients. Travelers, children, and older adults are also at risk \[[@pntd.0008293.ref002]\].

Currently, analysis of polymorphisms within the ribosomal internal transcribed spacer (ITS) is most commonly used for genotyping of *E*. *bieneusi*. Over 474 ITS genotypes have been identified, of which more than 96 have been detected in humans \[[@pntd.0008293.ref003], [@pntd.0008293.ref004]\]. Phylogenetic analysis indicated that these genotypes clustered into 11 groups (Group 1--11). Most *E*. *bieneusi* isolates causing human infections belonged to the zoonotic Group 1 \[[@pntd.0008293.ref005]\]. Nevertheless, there is an increasing number of reports have been showing that some Group-2-genotypes (I, J, BEB4 and BEB6) firstly detected in livestock or wild animals can also infect humans \[[@pntd.0008293.ref003], [@pntd.0008293.ref004]\]. Genotypes of other groups appear to be more host-specific, suggesting a low level of potential for zoonotic or cross-species transmission. However, this hypothesis needs to be confirmed because little information is available regarding these groups \[[@pntd.0008293.ref004]\].

In 2011, the first report emerged of *E*. *bieneusi* infecting humans in Jilin, China \[[@pntd.0008293.ref006]\], with 22.5% (9/40) of children with diarrheal disease testing positive for this pathogen. Over the last decade, the prevalence and genotype distribution of *E*. *bieneusi* in humans in China have been reported by several studies \[[@pntd.0008293.ref006]--[@pntd.0008293.ref015]\]. The study participants had widely variable characteristics (children with or without diarrhea, HIV-positive or -negative individuals, and other immunocompromised patients) \[[@pntd.0008293.ref006]--[@pntd.0008293.ref015]\] and the studies were conducted in diverse geographical locations (Jilin, Heilongjiang, Guangxi, Henan, Shanghai, Hubei, Chongqing, and Yunnan). However, no data are available regarding the prevalence and genetic characteristics of *E*. *bieneusi* isolates in the Xinjiang Uygur Autonomous Region (hereafter referred to as Xinjiang), China. Herein, we conducted a molecular epidemiological study of *E*. *bieneusi*, via sequencing of the ITS region, to understand the prevalence and genotypes of this pathogen in children in Xinjiang.

Materials and Methods {#sec002}
=====================

Ethics statement {#sec003}
----------------

All procedures complied with the ethical standards of the relevant national and institutional committees on human experimentation and with the principles laid out in the Helsinki Declaration of 1975, as revised in 2013. The study was approved by the Institutional Review Board of Henan Agricultural University (Approval No: IRC-HENAU-20160224-05). Written informed consent for participation in the study was obtained from the parent or guardian of each child after they were informed of the purposes and procedures of the study. Participants with possible presence of parasites received appropriate treatment according to local policies and national guidelines.

Sample collection {#sec004}
-----------------

The study was conducted from August 2017 to January 2019. Fresh stool samples were collected from children (age range: 2 to 6 years) at kindergartens in 11 counties in Southern Xinjiang ([Fig 1](#pntd.0008293.g001){ref-type="fig"}). After being informed of the study purpose and procedures by kindergarten staff, parents or guardians who agreed to their children's participation were given a plastic fecal collector labeled with a unique number. Fresh stool samples were collected in the morning. The fecal collector was then marked with the date and the participant's name, age, and sex. No diarrhea was observed during sampling. In total, 609 fecal samples were collected, transported to the laboratory and stored at 4°C.

![Geographic map of the sampling locations in Xinjiang, China.\
The figure was originally designed by the authors under the software ArcGIS 10.2. The original vector diagram imported in ArcGIS was adapted from Natural Earth ([http://www.naturalearthdata.com](http://www.naturalearthdata.com/)).](pntd.0008293.g001){#pntd.0008293.g001}

DNA extraction and PCR amplification {#sec005}
------------------------------------

Fresh fecal samples were processed within 24 h of transport to the laboratory. Genomic DNA was extracted from \~200 mg of each stool sample using the *E*.*Z*.*N*.*A* stool DNA kit (Omega Bio-tek, Norcross, GA) in accordance with the manufacturer's instructions. Extracted DNA was stored at -20°C until PCR was performed.

All samples were screened for the presence of *E*. *bieneusi* using a nested PCR targeting a \~390-bp fragment of the ITS in accordance with the method described by Sulaiman et al. \[[@pntd.0008293.ref016]\] with some optimization. PCR was performed in 25-μl reaction mixtures consisting of 2 μL of DNA preparation (or first PCR product), 1× PCR buffer, 200 μM dNTPs, 3 mM MgCl~2~, 260 nM primers, and 1.5 units of *Taq* DNA polymerase (Takara, Tokyo, Japan). PCR was performed in an Applied Biosystems 2720 thermal cycler (Applied Biosystems, Foster City, USA) using a program of 35 cycles, each consisted of denaturation at 94°C for 35 s, annealing at 55°C for 45 s, and extension for 45 s at 72°C; an initial denaturation step of 95°C for 5 min and a final extension step of 72°C for 10 min were also included. Outer primers were EBITS3 (5'-GGTCATAGGGATGAAGAG-3') and EBITS4 (5'-TTCGAGTTCTTTCGCGCTC-3'); EBITS1 (5'-GCTCTGAATATCTATGGCT-3') and EBITS2.4 (5'-ATCGCCGACGGATCCAAGTG-3') were used as nested primers for secondary PCR. Reagent-grade water and *E*. *bieneusi*-positive DNA (dairy cattle-derived genotype I DNA) were used as negative and positive controls, respectively.

Sequence and phylogenetic analyses {#sec006}
----------------------------------

Positive secondary PCR products were sequenced bidirectionally by GENEWIZ (Suzhou, China). The obtained sequences were assembled and edited using DNASTAR Lasergene EditSeq version 7.1.0 (<http://www.dnastar.com/>) and aligned with reference sequences downloaded from GenBank in the software Clustal X version 2.1 (<http://www.clustal.org/>).

The typical length of *E*. *bieneusi* ITS nucleotide sequence was 243 bp. Phylogenetic relationships were inferred by constructing a phylogenetic tree using Bayesian inference (BI) and the Monte Carlo Markov Chain method in MrBayes v3.2.6 (<http://mrbayes.sourceforge.net/>) and Fig-Tree v1.4.4 (<http://tree.bio.ed.ac.uk/software/figtree/>). Posterior probabilities were estimated based on 1,000,000 generations with four simultaneous tree building chains, with trees saved every 100^th^ generation. A 50% majority rule consensus tree for each analysis was constructed based on the final 75% of trees generated using BI.

Statistical analyses {#sec007}
--------------------

Prevalence of *E*. *bieneusi* with an associated 95% confidence interval (CI) was calculated using IBM SPSS Statistics ([www.ibm.com/products/spss-statistics](http://www.ibm.com/products/spss-statistics)). Fisher's exact test was used to compare the prevalence of *E*. *bieneusi* in different groups. A two-sided *p*-value of ≤0.05 was considered statistically significant.

Nucleotide sequence accession numbers {#sec008}
-------------------------------------

All nucleotide sequences obtained in this study were deposited in GenBank under accession numbers MN136770 to MN136778.

Results {#sec009}
=======

Prevalence of *E*. *bieneusi* {#sec010}
-----------------------------

Of the 609 fecal samples analyzed by nested PCR, 36 were positive for *E*. *bieneusi*, yielding an overall prevalence 5.9% (95% CI 4.0--7.9%). *E*. *bieneusi*-positive samples were detected in eight of the 11 counties involved in this study ([Table 1](#pntd.0008293.t001){ref-type="table"}). The highest prevalence was observed in Yopurga (17.5%, 11/63; 95% CI: 7.3--27.7%) followed by Baicheng (13.0%, 3/23; 95% CI: 0--29.0%). Prevalence ranged from 1.6% to 9.0% in the remaining six counties, and *E*. *bieneusi* was not detected in Hotan, Poskam or Kuqa ([Table 1](#pntd.0008293.t001){ref-type="table"}). Differences in *E*. *bieneusi* prevalence among counties in which the parasite was detected were statistically significant (*p* = 0.043).

10.1371/journal.pntd.0008293.t001

###### Prevalence and genotype distribution of *E*. *bieneusi* among children in different counties of southern Xinjiang.

![](pntd.0008293.t001){#pntd.0008293.t001g}

  County      No. of positives/ No. of samples   Prevalence (%) (95% CI)   Genotype (n)
  ----------- ---------------------------------- ------------------------- -------------------------------------------------------------------------------------------
  Tumushuke   1/62                               1.6 (0--5.6)              NIA1 (1)
  Payzawat    2/25                               8.0 (0--20.6)             NIA1 (2)
  Shufu       3/48                               6.3 (0--14.1)             D (1), NIA1 (2)
  Yopurga     11/63                              17.5 (7.3--27.7)          CXJH1 (1), D (4), NIA1 (6)
  Yecheng     8/89                               9.0 (2.5--15.5)           A (3), D (1), NIA1 (4)
  Hotan       0/80                               0                         
  Baicheng    3/23                               13.0 (0--29.0)            CHN6 (1), CXJH2 (1), CXJH3 (1)
  Poskam      0/35                               0                         
  Kuqa        0/38                               0                         
  Pishan      3/37                               8.1 (0--18.3)             EbpA (2), NIA1 (1)
  Lop         5/109                              4.6 (0.2--9.0)            EbpA (1), KB-1 (1), NIA1 (3)
  Total       36/609                             5.9 (4.0--7.9)            A (3), CHN6 (1), CXJH1 (1), CXJH 2 (1), CXJH 3 (1), D (6), EbpA (3), KB-1 (1), NIA1 (19),

*E*. *bieneusi* was detected in 6.7% (20/299, 95% CI: 3.7%--9.7%) and 5.2% (16/310, 95% CI: 2.5%--7.8%) of samples from boys and girls, respectively. Prevalence differences between gender groups were not significant (*p* \> 0.05) ([Table 2](#pntd.0008293.t002){ref-type="table"}).

10.1371/journal.pntd.0008293.t002

###### Prevalence and genotype distribution of *E*. *bieneusi* among children in southern Xinjiang by gender.

![](pntd.0008293.t002){#pntd.0008293.t002g}

  Gender   No. of positives/ No. of samples   Prevalence (%) (95% CI)   Genotype (n)
  -------- ---------------------------------- ------------------------- --------------------------------------------------------------------------------
  Boy      20/299                             6.7 (3.7--9.7)            A (2), CHN6 (1), D (3), EbpA (1), NIA1 (13)
  Girl     16/310                             5.2 (2.5--7.8)            A (1), CXJH1 (1), CXJH 2 (1), CXJH 3 (1), D (3), EbpA (2), KB-1 (1), NIA1 (6),

Genotype distribution of *E*. *bieneusi* {#sec011}
----------------------------------------

Nucleotide sequences of the ITS were analyzed for all 36 *E*. *bieneusi* PCR-positive samples. The results revealed nine distinct genotypes, including six known genotypes (A, CHN6, D, EbpA, KB-1, and NIA1) and three novel genotypes (CXJH1, CXJH2 and CXJH3) ([Table 1](#pntd.0008293.t001){ref-type="table"}). NIA1 was the most frequently-detected genotype (n = 19), followed by genotypes D (n = 6), A (n = 3), and EbpA (n = 3). The remaining genotypes were detected in one sample each.

Phylogenetic analysis {#sec012}
---------------------

Compared with genotype NIA1 (EF428628), the novel genotype CXJH1 displayed a single nucleotide polymorphism (SNP) at position 17 (G→A) of the ITS sequence. Genotypes CXJH2 and CXJH3 were characterized by two SNPs each (A43G and T201C in CXJH2; A3G and A43G for CXJH3) compared with genotype CHN6 (HM992514). Phylogenetic analysis was performed using the ITS region sequences to understand the genetic relationships among the novel *E*. *bieneusi* genotypes identified in this study and known genotypes. Genotypes NIA1, D, KB-1, A, EbpA, and the novel genotype CXJH1 clustered into one group (Group 1) and the remaining three genotypes (CHN6, CXJH2, and CXJH3) clustered in Group 2 together with the zoonotic genotypes I, J, and BEB6 ([Fig 2](#pntd.0008293.g002){ref-type="fig"}).

![Bayesian phylogenetic analysis of *E*. *bieneusi* ITS sequences.\
Statistically significant posterior probabilities are indicated at branches. Sample names include GenBank accession number followed by host and then genotype designation. The *E*. *bieneusi* genotype CSK2 (KY706128) from red kangaroo was used as the outgroup. Known and novel genotypes identified in this study are indicated by squares and triangles, respectively.](pntd.0008293.g002){#pntd.0008293.g002}

Discussion {#sec013}
==========

The average prevalence of *E*. *bieneusi* measured in humans in China is approximately 5.8% \[[@pntd.0008293.ref017]\], with the highest prevalence (22.5%, 9/40) reported in Changchun \[[@pntd.0008293.ref006]\] and the lowest (0.2%, 1/500) in Wuhan \[[@pntd.0008293.ref012]\]. The prevalence of *E*. *bieneusi* detected in the present study was 5.9%, and similar results have been reported in several previous studies. For example, in a previous study, the prevalence of *E*. *bieneusi* in children of various age categories and clinical presentations was 7.5% (19/225) \[[@pntd.0008293.ref010]\]. Similar prevalence was also reported in a contrast study conducted in Henan Province in China, in which 683 HIV-negative and 683 HIV-positive individuals were screened for the presence of *E*. *bieneusi*; 4.2% (29/683) and 5.7% (39/683), respectively, tested positive for this parasite \[[@pntd.0008293.ref008]\]. However, higher prevalence has also been reported in China, such as in a study which found that 11 of 93 (11.8%) fecal specimens collected from children with diarrheal disease in Chongqing were positive for *E*. *bieneusi* \[[@pntd.0008293.ref014]\]. Large differences in *E*. *bieneusi* prevalence in different regions in China have been reported by many studies, but the reasons underlying these differences remain unclear. *E*. *bieneusi* prevalence is associated with many factors, including but not limited to the immune status of the host, healthcare level, economic status and living conditions \[[@pntd.0008293.ref013]\]. To determine the specific factors responsible for prevalence differences, more epidemiological investigations will need to be conducted.

In this study, *E*. *bieneusi* NIA1 was the most frequently-detected genotype (52.8%, 19/36). NIA1 was first detected in an HIV-positive patient in Niamey, Niger in 2007 \[[@pntd.0008293.ref018]\]. Subsequently, NIA1 was detected in two hospitalized Acquired Immune Deficiency Syndrome (AIDS) patients in the Democratic Republic of the Congo in 2010 \[[@pntd.0008293.ref019]\], one HIV-positive patient in China in 2011 \[[@pntd.0008293.ref020]\], and one HIV-positive patient in the Democratic Republic of the Congo in 2012 \[[@pntd.0008293.ref021]\]. Surprisingly, *E*. *bieneusi* NIA1 has only been identified in HIV-positive patients in previous studies, but was the dominant genotype (52.8%, 19/36) in children in Southern Xinjiang in this study. Whether there is a correlation between the genotype NIA1 and the immune status of local children, or a geographical role in the distribution of this genotype, requires further investigation.

Genotype D was the second most prevalent genotype detected in this study. According to the few reports of human infection by this genotype in China, genotype D was frequently detected in children with diarrhea, HIV-positive patients, and HIV-negative individuals in Shanghai, Henan, Hubei, and Guangxi \[[@pntd.0008293.ref007], [@pntd.0008293.ref008], [@pntd.0008293.ref011], [@pntd.0008293.ref012]\]. Additionally, genotype D has also been detected in humans in at least 21 countries worldwide \[[@pntd.0008293.ref004]\] and in a vast range of animal species including companion animals, livestock, wildlife, rodents, and birds \[[@pntd.0008293.ref004], [@pntd.0008293.ref013]\]. In addition, genotype D has been detected in river water, wastewater, and combined sewer overflow in China \[[@pntd.0008293.ref022]--[@pntd.0008293.ref024]\] as well as in wastewater in Spain and Tunisia \[[@pntd.0008293.ref025], [@pntd.0008293.ref026]\]. Therefore, the zoonotic potential of *E*. *bieneusi* genotype D is established, and its transmission via the indirect fecal--oral route is a strong possibility.

Among the remaining known genotypes, KB-1, CHN6, and EbpA were first identified in nonhuman primates (NHPs), dogs, and pigs, respectively \[[@pntd.0008293.ref006], [@pntd.0008293.ref027], [@pntd.0008293.ref028]\]. Genotype EbpA has been detected in many hosts, including NHPs, sheep, goats, deer, dairy cattle, and humans \[[@pntd.0008293.ref004]\]. Moreover, in one of our previous studies genotypes D and EbpA have been detected in pigs in the same geographical area of Xinjiang (China) \[[@pntd.0008293.ref029]\]. This may indicate the animal origin of *E*. *bieneusi* in this area. Since all the samples involved here were collected from counties in rural area, the role of livestock in the circulation of this pathogen is nonnegligible in Xinjiang, China. Interestingly, ours is the first report of human infection by *E*. *bieneusi* genotypes KB-1 and CHN6.

According to the phylogenetic tree inferred in our study, the novel genotype CXJH1 clustered together with genotypes KB-1, A, and NIA1 in Group 1, potentially reflecting the zoonotic potential of these four genotypes. In contrast, genotypes CXJH2 and CXJH3 clustered together with genotype CHN6 in Group 2. Previous studies suggested that Group 2 was composed of *E*. *bieneusi* genotypes identified in ruminants. However, Group 2 genotypes have also increasingly been detected in human samples, suggesting their zoonotic potential \[[@pntd.0008293.ref007]\].

In conclusion, the results of our study showed that *E*. *bieneusi* infection occurs in children in Xinjiang, China. Unusually, genotype NIA1 was identified as the most prevalent genotype among the fecal samples examined. Further epidemiological studies need to be conducted to confirm the animal origin of *E*. *bieneusi* infection in this area.
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10 Apr 2020

Dear Dr. Zhang,

Thank you very much for submitting your manuscript \"Unusual dominant genotype NIA1 of Enterocytozoon bieneusi in children in Southern Xinjiang, China\" for consideration at PLOS Neglected Tropical Diseases. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. The reviewers appreciated the attention to an important topic. Based on the reviews, we are likely to accept this manuscript for publication, providing that you modify the manuscript according to the review recommendations.

Please prepare and submit your revised manuscript within 7 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email.  

When you are ready to resubmit, please upload the following:

\[1\] A letter containing a detailed list of your responses to all review comments, and a description of the changes you have made in the manuscript. 

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out

\[2\] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Thank you again for your submission to our journal. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don\'t hesitate to contact us if you have any questions or comments.

Sincerely,

Abdallah M. Samy, PhD

Deputy Editor

PLOS Neglected Tropical Diseases

Todd Reynolds

Deputy Editor

PLOS Neglected Tropical Diseases
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Reviewer\'s Responses to Questions

**Key Review Criteria Required for Acceptance?**

As you describe the new analyses required for acceptance, please consider the following:

**Methods**

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer \#1: -Are the objectives of the study clearly articulated with a clear testable hypothesis stated? YES

-Is the study design appropriate to address the stated objectives? YES

-Is the population clearly described and appropriate for the hypothesis being tested? YES

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested? YES

-Were correct statistical analysis used to support conclusions? YES

-Are there concerns about ethical or regulatory requirements being met? NO

Reviewer \#3: Yes

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Results**

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer \#1: -Does the analysis presented match the analysis plan? YES

-Are the results clearly and completely presented? YES

-Are the figures (Tables, Images) of sufficient quality for clarity? YES

Reviewer \#3: Yes

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Conclusions**

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer \#1: -Are the conclusions supported by the data presented? YES

-Are the limitations of analysis clearly described? YES

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study? YES

-Is public health relevance addressed? YES

Reviewer \#3: Yes

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Editorial and Data Presentation Modifications?**

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend "Minor Revision" or "Accept".

Reviewer \#1: Comment:

Question 2: - Lines 16-17: "Enterocytozoon bieneusi causes approximately 90% of reported cases of human microsporidiosis". Add: "mainly pathologies or intestinal disorders". Response: Thank you very much. We have revised this. Seen in Line 16.

The authors must put all words "mainly pathologies or intestinal disorders". In the manuscript is only \"Enterocytozoon bieneusi is the mainly pathologies\".

Reviewer \#3: Accept

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Summary and General Comments**

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer \#1: Dear Authors:

I want to thank the authors for the changes done and congratulate them for the work and research presented in the article. And I encourage them to continue in the same line for clearing doubts about the circulation and prevalence of this parasite.

Reviewer \#3: The author has already addressed the relevant questions and the authors have made the changes. I have just a few additional comments.

1\. "unusual dominant genotype NIA1" is missing in the abstract, please add it.

2\. Line 59, 'of which 96 have been...' should be revised to 'of which more than 96 have been...'

3\. Line 213, healthcare level also should be included here.

4\. Line 251, '...isolates identified in ruminants.'. Revised word 'isolates' to 'genotypes'.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosntds/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Dr. Fernando Izquierdo Arias.

Reviewer \#3: Yes: Jianping Cao
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While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, [https://pacev2.apexcovantage.com. PACE](https://pacev2.apexcovantage.com. PACE) helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.
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Please note that, as a condition of publication, PLOS\' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: <http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5>.
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To enhance the reproducibility of your results, PLOS recommends that you deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see <http://journals.plos.org/plosntds/s/submission-guidelines#loc-materials-and-methods>
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14 Apr 2020

Dear Dr. Zhang,

We are pleased to inform you that your manuscript \'Unusual dominant genotype NIA1 of Enterocytozoon bieneusi in children in Southern Xinjiang, China\' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution\'s press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Abdallah M. Samy, PhD

Deputy Editor

PLOS Neglected Tropical Diseases

Todd Reynolds

Deputy Editor

PLOS Neglected Tropical Diseases
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12 Jun 2020

Dear Dr. Zhang,

We are delighted to inform you that your manuscript, \"Unusual dominant genotype NIA1 of Enterocytozoon bieneusi in children in Southern Xinjiang, China,\" has been formally accepted for publication in PLOS Neglected Tropical Diseases.

We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc\...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article\'s publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases
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